MétaCan
Menu
← Back to cohort
Record W4411413832 · doi:10.1016/j.ard.2025.06.1860

ABS0552 VARIATIONS IN TACROLIMUS WHOLE BLOOD CONCENTRATIONS DURING PREGNANCY AND ITS IMPLICATIONS FOR THERAPEUTIC DRUG MONITORING: A SYSTEMATIC REVIEW AND META-ANALYSIS

2025· review· en· W4411413832 on OpenAlexaffabout
R. Farhat, A. Mendel, I. Malhamé, Sergio Grunbaum, S. Bernatsky, Évelyne Vinet

Bibliographic record

VenueAnnals of the Rheumatic Diseases · 2025
Typereview
Languageen
FieldMedicine
TopicPregnancy and Medication Impact
Canadian institutionsMcGill University Health Centre
Fundersnot available
KeywordsMedicineTacrolimusTherapeutic drug monitoringDrugMeta-analysisPregnancyWhole bloodPharmacologyInternal medicineIntensive care medicineBioinformatics

Abstract

fetched live from OpenAlex

Background: Tacrolimus is a pregnancy-compatible immunosuppressive increasingly used in systemic lupus erythematosus (SLE) pregnancies. Physiological changes throughout pregnancy impact tacrolimus pharmacokinetics, altering the drug's whole blood concentrations during gestation. However, data is very limited to guide clinicians caring for pregnant women receiving tacrolimus in interpreting tacrolimus trough levels and adjusting the dosage. Objectives: By completing a systematic literature review, we evaluated the variation of maternal tacrolimus trough levels and dosage during pregnancy in SLE and non-SLE women. Methods: Using a combination of relevant search terms and keywords, we systematically searched Embase, Ovid, PubMed, Web of Science and Cochrane Library up to September 2024. All observational studies which measured tacrolimus trough levels during pregnancy were included without language or date restriction. Records which were reviews, case reports, abstracts only, non-human, and had no tacrolimus trough levels during pregnancy were excluded from the review. We used the random-effects model where mean trough levels and doses of tacrolimus before pregnancy, during pregnancy and in the postpartum were analyzed and expressed as standardized mean difference (SMD) or mean difference (MD), with 95% confidence intervals (CI). Results: Of 404 records identified, 282 were screened based on title and abstract, of which 53 full-text articles were assessed for eligibility. Eighteen articles were included in the systematic review and 13 in the meta-analysis, of which only 2 specifically assessed tacrolimus blood levels in SLE pregnancies, while the remainder addressed tacrolimus monitoring in pregnant post-transplant recipients. Whole blood concentrations of tacrolimus significantly decreased during pregnancy compared to pre-pregnancy levels (SMD -1.05; 95% CI -1.72, -0.37) and significantly increased in the postpartum compared to the levels during gestation (SMD 0.87; 95% CI 0.37, 1.37) (Figure 1A and B). The mean differences in tacrolimus trough levels were -1.56 ng/ml (95%CI -2.82, -0.31) between first trimester and before pregnancy, -0.49 ng/ml (95% CI -1.04, -0.07) between second and first trimesters, 0.63 ng/ml (95% CI 0.30, 0.96) between third and second trimesters, and 1.28 ng/ml (95% CI 0.60, 1.96) between the postpartum and third trimester. The variation in tacrolimus levels during pregnancy was usually addressed by increasing the drug dose during pregnancy vs pre-pregnancy (MD 1.35 mg/dayl 95% CI 0.23, 2.48) and decreasing the dose in the postpartum vs pregnancy (MD -0.92 mg/day; 95% CI -1.8, -0.01) (Figure 1C and D). Conclusion: Tacrolimus whole-blood concentrations decrease in the first and second trimesters, then increase back to pre-pregnancy levels in the postpartum. Tacrolimus dosage in pregnancy is increased to maintain tacrolimus trough levels within the usual therapeutic ranges. Increasing drug dosage could elevate the bio-effective fraction of tacrolimus (not measured by trough levels), raising concerns for safety and efficacy of dose augmentation during pregnancy. Further research is needed to guide clinicians in adjusting tacrolimus dosage in SLE and post-transplant pregnancies to optimize therapeutic drug monitoring in these high-risk populations. Figure 2Combined means of tacrolimus doses (mg/day) and whole-blood trough levels (ng/ml) before pregnancy, at each trimester and in the postpartum (10 studies, n=182). REFERENCES: NIL . Acknowledgements: This work was supported by a student bursary from the Canadian Mother-Child Cohort (CAMCCO) and by a funding award from the Canadian Rheumatology Association (CRA) - Canadian Initiative for Outcomes in Rheumatology Care (CIORA). Disclosure of Interests: None declared . © The Authors 2025. This abstract is an open access article published in Annals of Rheumatic Diseases under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). Neither EULAR nor the publisher make any representation as to the accuracy of the content. The authors are solely responsible for the content in their abstract including accuracy of the facts, statements, results, conclusion, citing resources etc.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.012
metaresearch head score (Gemma)0.032
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Meta-analysis · Consensus signal: none
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.016
Threshold uncertainty score0.063

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0120.032
Meta-epidemiology (narrow)0.0020.001
Meta-epidemiology (broad)0.0160.029
Bibliometrics0.0080.010
Science and technology studies0.0010.001
Scholarly communication0.0030.002
Open science0.0020.001
Research integrity0.0020.002
Insufficient payload (model declined to judge)0.0060.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.138
GPT teacher head0.420
Teacher spread0.282 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designMeta-analysis
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes2
Has abstractyes

Explore more

Same venueAnnals of the Rheumatic Diseases→Same topicPregnancy and Medication Impact→French-language works237,207→